➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
McKesson
Boehringer Ingelheim
Merck

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MEXATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Mexate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002798 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 3 1996-08-01 Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002970 506U78 in Treating Patients With Refractory Hematologic Cancer Completed Children's Cancer Group Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 506U78 in Treating Patients With Refractory Hematologic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003702 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Completed Eastern Cooperative Oncology Group Phase 3 1999-06-01 Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003702 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Completed National Cancer Institute (NCI) Phase 3 1999-06-01 Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mexate

Condition Name

Condition Name for Mexate
Intervention Trials
Untreated Adult Acute Lymphoblastic Leukemia 16
Recurrent Adult Acute Myeloid Leukemia 13
Untreated Childhood Acute Lymphoblastic Leukemia 13
Adult Acute Myeloid Leukemia in Remission 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mexate
Intervention Trials
Leukemia 60
Precursor Cell Lymphoblastic Leukemia-Lymphoma 49
Leukemia, Lymphoid 49
Lymphoma 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mexate

Trials by Country

Trials by Country for Mexate
Location Trials
Canada 107
Australia 43
New Zealand 17
Japan 8
Puerto Rico 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mexate
Location Trials
Washington 40
California 37
Ohio 36
Pennsylvania 35
New York 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mexate

Clinical Trial Phase

Clinical Trial Phase for Mexate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 27
Phase 2/Phase 3 1
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mexate
Clinical Trial Phase Trials
Completed 27
Recruiting 23
Not yet recruiting 19
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mexate

Sponsor Name

Sponsor Name for Mexate
Sponsor Trials
National Cancer Institute (NCI) 81
Children's Oncology Group 17
Fred Hutchinson Cancer Research Center 12
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mexate
Sponsor Trials
NIH 89
Other 72
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Express Scripts
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.